First extensive immune profiling of sarcomas shows some types may be susceptible to immunotherapy; Fred Hutch hosts first-of-its-kind regional conference for science communicators; and Pathway that regulates organ size may also underlie tumors’ resistance to certain chemotherapy drugs.
A biopolymer sponge delivers cancer-shrinking T-cell therapy in preclinical study
April 24, 2017
| By Sabrina Richards / Fred Hutch News Service
A dissolving scaffold developed by Dr. Matthias Stephan delivers engineered anti-tumor immune cells to crowded masses of tumor cells and recruits the native immune system to mount a second-wave attack on the cancer.
‘Functional genomics’ method aims to marry three powerful techniques to speed personalized cancer treatments to patients
March 31, 2017
| By Rachel Tompa / Fred Hutch News Service
Dr. Christopher Kemp is confident that the answer to personalized cancer treatment is written in the molecules inside each patient’s tumor, we just need to figure out how to separate the wheat from the chaff.
A Fred Hutch researcher and breast cancer survivor talks about her inherited mutation and how it helped guide her decisions
Nov. 8, 2016
| By Diane Mapes / Fred Hutch News Service
As research sheds ever more light on hereditary cancers and the genes that cause them, a portion of the population is being faced with some very difficult choices. Do you test or not test? Share information about deadly mutations with relatives or keep it to yourself? Get preventive surgery or blindly hope cancer doesn’t strike? A Fred Hutch researcher, BRCA carrier and cancer survivor, takes us through her decision-making process.
Flexible, precision-medicine trial ‘driven by doing what is best for the individual patient’
Oct. 4, 2016
| By Susan Keown / Fred Hutch News Service
Called “Precision Promise,” this new nationwide precision-medicine trial in pancreatic cancer seeks to turn the concept of clinical trials on its head: Rather than finding participants for a given experimental treatment study, the approach finds the right treatment for a given patient at a given time.
Fred Hutch is proud to be an Equal Opportunity and VEVRAA Employer. We are committed to cultivating a workplace in which diverse perspectives and experiences are welcomed and respected. We do not discriminate on the basis of race, color, religion, creed, ancestry, national origin, sex, age, disability, marital or veteran status, sexual orientation, gender identity, political ideology, or membership in any other legally protected class. We are an Affirmative Action employer. We encourage individuals with diverse backgrounds to apply and desire priority referrals of protected veterans. Read the EEO is the Law poster here.